Delirium: surveillance review proposal
A review has been undertaken to decide whether NICE should update this guideline and whether this guideline should be transferred to the static guidance list.
Registered stakeholders for the guideline are invited to comment on the provisional review decision via this website.
Individuals and organisations not registered as stakeholders are not able to comment, we recommend that you register as a stakeholder or you contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them.
Note that the provisional review decision presented here does not constitute the Institute's formal decision on this topic. The decision is provisional and may change after consultation.
Consultation dates: 9am on 30 October 2014 to 5pm on 13 November 2014
Consultation document:
How to submit your comments:
Please provide all responses to the review proposal documents using the comments proforma (ensuring all relevant fields are completed, including your organisation’s full name) and forward this electronically by 5pm on 13 November 2014 at the very latest to this email address: Delirium.Surveillance@nice.org.uk
The Institute is unable to accept:
- Comments from non-registered organisations – if you wish your comments to be considered please register via the NICE website
- Comments from individuals – please contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them.
- Comments received after the consultation deadline (5pm)
- Comments that are not on the correct proforma
- More than one response per stakeholder organisation
- Confidential information or other material that you would not wish to be made public
- Personal medical information about yourself or another person from which your or the person’s identity could be ascertained.
What will happen to your comments:
- Comments from registered stakeholders and nominated expert reviewers ONLY will be sent to the review team at the end of the consultation. These will inform the final decision made by the NICE Guidance Executive.
- No action will be taken upon receipt of personal, individual comments, comments from non-registered organisations and late comments.
Anticipated review decision date: December 2014
Further information
· More information on NICE’s guideline review process
This page was last updated: 28 October 2014
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Appendix D diagnostic test accuracy - included studies (PDF 182 KB)
-
-
Appendix D non pharmacological risk factors - included studies (PDF 90 KB)
-
Appendix D pharmacological risk factors - included studies (PDF 49 KB)
-
Appendix E consequences of cohort studies - methodological quality (PDF 125 KB)
-
Appendix E diagnostic accuracy tests - methodological quality (PDF 172 KB)
-
Appendix E epidemiology - methodological quality (PDF 168 KB)
-
Appendix E non-pharmacological risk factors cohort studies - methodological quality (PDF 44 KB)
-
Appendix E pharmacological risk factors cohort studies - methodological quality (PDF 29 KB)
-
Appendix E patient information - methodological quality (PDF 213 KB)
-
Appendix F consequences of - multivariate risk factors (PDF 185 KB)
-
Appendix F - non-pharmacological risk factors - multivariate risk factors (PDF 293 KB)
-
Appendix F pharmacological risk factors - multivariate risk factors (PDF 63 KB)
-
Appendix G diagnostic test accuracy - excluded studies (PDF 128 KB)
-
Appendix G adverse effects review - excluded studies (PDF 121 KB)
-
-
Appendix G epidemiology review - excluded studies (PDF 146 KB)
-
Appendix G non-pharmacological risk factors - excluded studies (PDF 71 KB)
-
Appendix G information for patients review - excluded studies (PDF 118 KB)
-
Appendix G pharmacological risk factors - excluded studies (PDF 55 KB)
-
-
-
-
-
Consultation table and with developers responses (PDF 1.02 MB)
-
Pre-publication check - stakeholder comments/developer responses (PDF 49 KB)
-
-
-
-
-
Appendix D - Adverse Effects - Included studies (PDF 121 KB)
-
Appendix D - Consequences of - Included studies (PDF 155 KB)
-
Appendix D - Diagnostic Test Accuracy - Included Studies (PDF 182 KB)
-
-
Appendix D - Non pharmacological Risk factor - Included studies (PDF 44 KB)
-
Appendix D - Pharma Nonpharma Prevention Treatment - Included studies (PDF 170 KB)
-
Appendix D - Pharmacological Risk factors - Included studies (PDF 49 KB)
-
-
Appendix E - Diagnostic Accuracy Tests Methodological Quality (PDF 172 KB)
-
-
-
-
Appendix E - Pharma NonPharma Prevention Treatment (PDF 107 KB)
-
Appendix E - Pharmacological Risk Factors review - Randomised controlled trials (PDF 23 KB)
-
Appendix E - Pharmacological Risk Factors review - cohort studies (PDF 30 KB)
-
-
Appendix H - Recommendations for Future Research (PDF 75 KB)
-
-
-
-
Consultation table and with developers responses (PDF 1.02 MB)